Company: SLDE
Filing Date: 2025-03-10
Form Type: DRS/A
Source: 0000950123-25-003025
Chunk: 106

Company: Slide Insurance Holdings, Inc.
Filing Date: 2025-03-10
Form: DRS/A
Chunk 106
---
 |     |   |       |     |   |
| Dilution per share to new investors                                                   |     |   |       |     | $ |

A $1.00 increase or decrease in the assumed initial public offering price of $ per share, the midpoint of the price range set forth on the cover of this prospectus, would increase or decrease pro forma net tangible book value by $ million, or $ per share, and would increase or decrease the dilution per share to investors in this offering by $ , based on the assumptions set forth above. 71

The following table sets forth, on a pro forma basis, as of December 31, 2024, the number of shares of common stock purchased from Slide, the total consideration paid, or to be paid, and the average price per share paid, or to be paid, by existing stockholders and by the new investors, at an assumed initial public offering price of $ per share, the midpoint of the range set forth on the cover page of this prospectus, before deducting estimated underwriting discounts and commissions and offering expenses payable by Slide:

|                       |     | Shares Purchased 
 Number           |     | Percent |     |   |     | Total Consideration 
 Amount              |     | Percent |     |   |     | Average Price 
 Per Share     |
|:----------------------|:----|:-----------------|:----|:--------|----:|:--|:----|:--------------------|:----|:--------|----:|:--|:----|:--------------|
| Existing stockholders |     |                  |     |         |     | % |     | $                   |     |         |     | % |     |               |
| New investors         |     |                  |     |         |     |   |     |                     |     |         |     |   |     |               |
| Total                 |     |                  |     |         | 100 | % |     | $                   |     |         | 100 | % |     |               |

The foregoing tables assume no exercise of the underwriters’ over-allotment option or of outstanding stock options after December 31, 2024. At December 31, 2024, 2,696,000 shares of common stock were subject to outstanding options, at a weighted average exercise price of $4.64. At December 31, 2024, 386,784 shares of common stock were subject to the vesting and